ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015
Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Cutaneous Acral Presentation of Indolent Mantle Cell Lymphoma With Prominent Nail Involvement and Atypical Immunophenotype.Journal of cutaneous pathology · 2026Article
- Epidemiological, clinical and therapeutic profiles of mantle cell lymphoma cared for in a Moroccan center: a review of 14 cases.The Pan African medical journal · 2024Article
- Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.Blood advances · 2023Article
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation.Virchows Archiv : an international journal of pathology · 2023Review
- How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.Current oncology (Toronto, Ont.) · 2021Review
- Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma.Genes, chromosomes & cancer · 2021Article
- The pathologic diagnosis of mantle cell lymphoma.Histology and histopathology · 2021Review
- Clinicopathological and Immunohistochemical Profile of Mantle Cell Lymphoma: An Institutional Experience.Cureus · 2021Article
- Article
- Cryptic insertions of the immunoglobulin light chain enhancer region nearHaematologica · 2020Article
- Highly sensitive and specificHaematologica · 2020Article
- Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.International journal of molecular sciences · 2019Review
- AL amyloidosis with a localized B cell neoplasia.Virchows Archiv : an international journal of pathology · 2019Article
- CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.Oncotarget · 2018Article
- Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.Blood advances · 2017Article
- Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.Current oncology reports · 2017Review
- The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.Virchows Archiv : an international journal of pathology · 2016Review
- New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015-December 2015.Journal of hematopathology · 2016Review
- The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Haematologica · 2016Review
- SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma.Biomarker research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma is a mature lymphoid neoplasm characterized by the t(11;14)(q13;q32) and cyclin D1 overexpression. SOX11 is a transcription factor commonly overexpressed in these tumors but absent in most other mature B-cell lymphomas whose function is not well understood. Experimental studies have shown that silencing of SOX11 in mantle cell lymphoma cells promotes the shift from a mature B cell into an early plasmacytic differentiation phenotype, suggesting that SOX11 may contribute to tumor development by blocking the B-cell differentiation program. The relationship between SOX11 expression and terminal B-cell differentiation in primary mantle cell lymphoma and its relationship to the plasmacytic differentiation observed in occasional cases is not known. In this study we have investigated the terminal B-cell differentiation phenotype in 60 mantle cell lymphomas, 41 SOX11-positive and 19 SOX11-negative. Monotypic plasma cells and lymphoid cells with plasmacytic differentiation expressing cyclin D1 were observed in 7 (37%) SOX11-negative but in none of 41 SOX11-positive mantle cell lymphomas (P<0.001). Intense cytoplasmic expression of a restricted immunoglobulin light chain was significantly more frequent in SOX11-negative than -positive tumors (58 vs 13%) (P=0.001). Similarly, BLIMP1 and XBP1 expression was also significantly more frequent in SOX11-negative than in -positive cases (83 vs 34% and 75 vs 11%, respectively) (P=0.001). However, no differences in the expression of IRF4/MUM1 were observed among these subtypes of mantle cell lymphoma. In conclusion, these results indicate that SOX11-negative mantle cell lymphoma may be a particular subtype of this tumor characterized by more frequent morphological and immunophenotypic terminal B-cell differentiation features that may be facilitated by the absence of SOX11 transcription factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.